Bristol Myers (BMY) Q1 profits rise 4% with $11.49 billion revenue
Published on · Source: finance.yahoo.com
AI Summary
Summarized by AI from the source belowBristol Myers Squibb (BMY) reported Q1 adjusted earnings of $1.58 per share, exceeding analysts' expectations of $1.42, with revenue of $11.49 billion also surpassing the forecast of $10.9 billion. Eliquis, partnered with Pfizer, generated $4.14 billion in sales, an increase of 16% year-over-year. Sales from the growth portfolio rose 12% to $6.23 billion, while sales of Opdivo fell 5% to $2.15 billion. The company reaffirmed its 2026 revenue outlook of $46.0 billion to $47.5 billion and adjusted earnings of $6.05 to $6.35 per share.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
About Bristol-Myers Squibb Company (BMY)
Bristol Myers Squibb is a major pharmaceutical company focused on oncology and immunology.
The Health Care sector covers pharmaceutical, biotech, device and managed-care companies.
Earlier BMY news
- Bristol-Myers Squibb (BMY) Offers Low Volatility and High Yield
- BMY Stock Rating Reiterated at Buy by Guggenheim
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
